Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial to Assess the Long Term Safety of Ciclesonide, Applied as a Nasal Spray (200 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 12 Years and Older
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Dec 2016
Price :
$35
*
At a glance
- Drugs Ciclesonide (Primary)
- Indications Perennial allergic rhinitis
- Focus Registrational; Therapeutic Use
- Sponsors ALTANA Pharma
- 05 Nov 2010 New trial record.